Compare Natera Inc. Common Stock (NTRA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Texas Instruments Incorporated — how do they compare? Natera Inc. Common Stock trades at $386.99 (market cap $57.03B), while Texas Instruments Incorporated trades at $276.32 (market cap $256.30B). The key difference: Texas Instruments Incorporated is far larger — about 4.5× Natera Inc. Common Stock's market cap, and Texas Instruments Incorporated pays a 2.17% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| NTRA | TXN | |
|---|---|---|
Market Cap | $57.03B | $256.30B |
Volume | 1,131,157 | 6,924,604 |
Sector | Health | Technology |
52-Week High | $425.64 | $332.35 |
52-Week Low | $179.42 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $56.18B | $263.35B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Texas Instruments (TXN) trades at $287.85, up 2.17% with strong technical support at $278 and resistance at $288. The company shows improving fundamentals with Q2 2026 EPS beating expectations at $2.14 versus $1.94, and revenue growth accelerating from $17.7B in 2025 to projected $19.5B in 2026. Operating cash flow strengthened to $7.15B in 2025, supporting consistent dividend payments.
TXN presents a compelling investment case with 47.7% analyst buy ratings and $325 consensus price target offering 13% upside. Key risks include premium valuation (P/E 43.75) and rising debt-to-asset ratio (40.61% in 2025). The data center segment's doubling sales and AI-driven semiconductor demand provide growth catalysts, though competitive pressures and cyclical industry dynamics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
